https://www.theguardian.com/science...sults-t-cell-therapy-research-clinical-trials
To administer the T-cell therapy, doctors remove immune cells from patients, tagging them with “receptor” molecules that target a specific cancer, as other T-cells target the flu or infections. They then infuse the cells back in the body.
“There are reasons to be optimistic, there are reasons to be pessimistic,” said Riddell, of the Fred Hutchinson Cancer Research Center in Washington state. He added that the researchers believe that lowering the dose of T-cells can reduce the risk of side-effects.
“T-cells are a living drug, and in particular they have the potential to persist in our body for our whole lives.”
Interesting article....
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.50 |
Change
0.070(0.61%) |
Mkt cap ! $243.1M | |||
| Open | High | Low | Value | Volume |
| $11.45 | $11.50 | $11.32 | $90.21K | 7.885K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 53 | $11.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.50 | 2061 | 1 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |